In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: DexCom’s current price exceeds all primary valuation methods, indicating significant overvaluation with a high-confidence fair value of $61.63 and implied downside near 29%. Monte Carlo simulations show extensive downside risk, with a median valuation at $35.86 and 100% of scenarios below current price. Despite excellent financial health and profitability, growth prospects appear moderate, limiting upside potential.